Currency In USD
| Previous Close | 1.13 |
| Open | 1.15 |
| Day High | 1.15 |
| Day Low | 1.09 |
| 52-Week High | 8.62 |
| 52-Week Low | 1.02 |
| Volume | 17,481 |
| Average Volume | 109,008 |
| Market Cap | 911,401 |
| PE | -0.16 |
| EPS | -6.86 |
| Moving Average 50 Days | 1.43 |
| Moving Average 200 Days | 2.39 |
| Change | 0 |
60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial
GlobeNewswire Inc.
Mar 11, 2026 11:24 AM GMT
All three patients enrolled in study have been cured, confirming high cure rate of tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publicationCompany calls for existing babesiosis treatment guidelines to be reviewed in light o
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
GlobeNewswire Inc.
Feb 02, 2026 1:01 PM GMT
GoodRx to offer prescription savings of up to 30% for ARAKODA® (tafenoquine)Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategyPartnership will improve the affordability of ARAKODA at over
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
GlobeNewswire Inc.
Jan 28, 2026 1:01 PM GMT
Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription usesWASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXT